2025年全球视网膜和玻璃体疾病市场报告

预计未来几年玻璃体视网膜疾病市场规模将强劲成长。到 2029 年，该市场规模将以 7.9% 的年复合成长率（CAGR）到 63 亿美元。预测期内的增长可归因于老龄化黄斑部病变病变盛行率的上升、糖尿病视网膜病变发生率的上升、再生干细胞疗法投资的增加、眼科疾病医疗支出的增加、对视网膜疾病早期发现意识的增强以及政府的支持措施。在此期间，预计的主要趋势包括基于人工智慧的视网膜疾病检测、机器人辅助玻璃体视网膜手术、基于奈米技术的药物传输系统、用于即时眼部监测的智慧隐形眼镜、超高解析度自适应光学成像以及生物分解性的玻璃体内植入。

糖尿病视网膜病变盛行率的不断上升预计将在未来几年推动玻璃体视网膜疾病市场的成长。糖尿病视网膜病变是眼科疾病。随着糖尿病患者数量的增加，这种疾病也变得越来越普遍，其主要原因是久坐的生活方式和血糖控制不佳，这些都会导致视网膜血管受损。玻璃体视网膜疾病的治疗对于控製糖尿病视网膜病变、保护视力以及透过解决玻璃体出血和牵引性视网膜剥离等问题来最大限度地减少视网膜的进一步损害至关重要。例如，澳洲政府机构澳洲健康与福利研究所于2024年10月报告称，2022-23年期间，筛检的原住民中，1.8%的人接受了糖尿病视网膜病变治疗，年龄标准化治疗率为1.3%，而非原住民澳洲人的这一比例为1.5%。因此，糖尿病视网膜病变发生率的上升正在推动玻璃体视网膜疾病市场的扩张。

玻璃体视网膜疾病市场的主要企业正在开发原发性玻璃体视网膜淋巴瘤（一种罕见且原发性的视网膜癌）的先进疗法，例如基于胺基甲基叶酸的疗法。这些治疗方法透过玻璃体内注射化疗药物胺基甲基叶酸来抑制视网膜和玻璃体内的癌细胞，从而提供强化有效的治疗。例如，2022年12月，美国生技公司Aldeila Therapeutics宣布已成功与FDA就ADX-2191举行新药认证申请前（pre-NDA）会议。该产品是一种新型无防腐剂的胺基甲基叶酸製剂，旨在治疗原发性玻璃体视网膜淋巴瘤（PVRL），为这种罕见疾病提供了一种有希望的解决方案。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球玻璃体视网膜疾病PESTEL分析（政治、社会、科技、环境、法律因素、驱动因素与限制因素）
• 最终用途产业分析
• 全球玻璃体视网膜疾病市场：成长率分析
• 全球玻璃体视网膜疾病市场表现：规模与成长，2019-2024
• 全球玻璃体视网膜疾病市场预测：规模与成长，2024-2029 年，2034 年
• 全球玻璃体视网膜疾病总目标市场（TAM）

第六章市场区隔

• 全球玻璃体视网膜疾病市场类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
• 视网膜撕裂
• 视网膜剥离
• 糖尿病视网膜病变
• 黄斑部病变
• 黄斑裂孔
• 其他类型
• 全球玻璃体视网膜疾病市场（依诊断、表现及预测），2019-2024 年、2024-2029 年、2034 年
• 数位萤光造影
• 光学同调断层扫描
• 海德堡视网膜断层扫描
• 靛氰绿造影萤光
• 其他诊断
• 全球玻璃体视网膜疾病市场（依治疗、表现及预测），2019-2024 年、2024-2029 年、2034 年
• 外科手术
• 药品
• 其他治疗方法
• 全球玻璃体视网膜疾病市场：依通路、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 医院药房
• 网路药局
• 零售药局
• 全球玻璃体视网膜疾病市场：按最终用户、业绩和预测，2019-2024 年、2024-2029 年、2034 年
• 医院
• 居家护理
• 专科诊所
• 其他最终用户
• 全球视网膜及玻璃体疾病市场按视网膜裂孔类型细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 萎缩性视网膜裂孔
• 视网膜撕裂
• 马蹄形视网膜裂孔
• 巨大视网膜裂孔
• 全球视网膜玻璃体疾病市场，依视网膜剥离类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 孔源性视网膜剥离
• 牵引性视网膜剥离
• 渗出性视网膜剥离
• 全球玻璃体视网膜疾病市场，依糖尿病视网膜病变类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 非增生性糖尿病视网膜病变
• 增生性糖尿病视网膜病变
• 糖尿病黄斑部水肿
• 全球玻璃体视网膜疾病市场按黄斑部病变类型细分、表现和预测，2019-2024 年、2024-2029 年、2034 年
• 干性黄斑部病变
• 湿性黄斑部病变
• 全球玻璃体视网膜疾病市场黄斑裂孔细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 全层黄斑裂孔
• 板层黄斑裂孔
• 牵引性黄斑裂孔
• 全球视网膜和玻璃体疾病市场，按类型细分，实际和预测，2019-2024 年、2024-2029 年、2034 年
• 视网膜前膜
• 视网膜静脉阻塞
• 视网膜动脉阻塞
• 视网膜色素变性
• 葡萄膜炎
• 玻璃体积血
• 黄斑部水肿
• 中心性浆液性视网膜病变
• 增生性玻璃体视网膜病变

第七章 区域和国家分析

• 全球玻璃体视网膜疾病市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 全球玻璃体视网膜疾病市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

• 视网膜与玻璃体疾病市场：竞争格局
• 视网膜和玻璃体疾病市场：公司简介
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

• Bayer AG
• Novartis AG
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Baxter International
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co. Ltd.
• Topcon Corporation
• Ocular Therapeutix Inc.
• Carl Zeiss Meditec AG
• EyePoint Pharmaceuticals Inc.
• Kodiak Sciences Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

• 2029年视网膜和玻璃体疾病市场：提供新机会的国家
• 2029年玻璃体视网膜疾病市场：细分领域带来新机会
• 2029年视网膜与玻璃体疾病市场：成长策略
  • 基于市场趋势的策略
  • 竞争对手的策略

第36章 附录

Vitreoretinal disorder encompasses a group of eye conditions that impact the retina and the vitreous humor, both of which are essential for preserving the eye's shape and ensuring visual clarity. These conditions can lead to progressive vision impairment and often require advanced diagnostic tools and specialized medical or surgical treatments for proper management.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or hole in the retina, the light-sensitive layer at the back of the eye. Diagnosis involves various techniques such as digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, among others. Treatment options include surgery, medication, and additional approaches. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and serve a range of end users including hospitals, home care settings, specialty clinics, and others.

The vitreoretinal disorder market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vitreoretinal disorder market size has grown strongly in recent years. It will grow from$4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of diabetic retinopathy, an aging population, increased awareness of retinal diseases, the expansion of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.

The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to$6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The projected growth in the forecast period can be attributed to the rising prevalence of age-related macular degeneration, an increasing incidence of diabetic retinopathy, growing investment in regenerative stem cell therapies, higher healthcare spending on eye diseases, greater awareness of early retinal disease detection, and supportive government initiatives. Key trends expected during this period include AI-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery systems, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.

The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market in the years ahead. Diabetic retinopathy is an eye disease resulting from damage to the retinal blood vessels caused by prolonged high blood sugar levels in individuals with diabetes. This condition is becoming more common due to the growing number of diabetes cases, largely fueled by sedentary lifestyles and inadequate blood sugar control, which lead to retinal vascular damage. Vitreoretinal disorder treatment is essential for managing diabetic retinopathy by addressing issues such as vitreous hemorrhage and tractional retinal detachment, thus helping to preserve vision and minimize further retinal harm. For example, in October 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that during 2022-23, 1.8% of screened First Nations individuals received treatment for diabetic retinopathy, with an age-standardized treatment rate of 1.3%, compared to 1.5% for non-Indigenous Australians. Therefore, the increasing incidence of diabetic retinopathy is contributing to the expansion of the vitreoretinal disorder market.

Leading companies in the vitreoretinal disorder market are developing advanced therapies, such as methotrexate-based treatments, to target primary vitreoretinal lymphoma-a rare and aggressive form of retinal cancer. This approach involves the intravitreal administration of methotrexate, a chemotherapy drug, to suppress cancerous cells in the retina and vitreous, providing a focused and effective treatment. For instance, in December 2022, Aldeyra Therapeutics Inc., a biotechnology company based in the U.S., announced a successful pre-New Drug Application (pre-NDA) meeting with the FDA regarding ADX-2191. This product is a novel, preservative-free methotrexate formulation designed to treat primary vitreoretinal lymphoma (PVRL), offering a promising solution for this rare condition.

In July 2024, Merck & Co. Inc., a U.S.-based pharmaceutical giant, acquired Eyebiotech Limited (EyeBio) for $3 billion. This strategic move aims to expand Merck's portfolio in the field of ophthalmology by adding Restoret (EYE103), a promising therapy for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Eyebiotech Limited, headquartered in the UK, is a clinical-stage biotech firm focused on developing treatments for retinal disorders, including vitreoretinal diseases.

Major players in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., and Clearside Biomedical.

North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in vitreoretinal disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vitreoretinal Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vitreoretinal disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vitreoretinal disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vitreoretinal disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Retinal Tear; Retinal Detachment; Diabetic Retinopathy; Macular Degeneration; Macular Hole; Other Types
• 2) By Diagnosis: Digital Fluorescein Angiography; Optical Coherence Tomography; Heidelberg Retinal Tomography; Indocyanine Green Angiography; Other Diagnosis
• 3) By Treatment: Surgery; Medication; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Retinal Tear: Atrophic Retinal Tear; Operculated Retinal Tear; Horseshoe Retinal Tear; Giant Retinal Tear
• 2) By Retinal Detachment: Rhegmatogenous Retinal Detachment; Tractional Retinal Detachment; Exudative Retinal Detachment
• 3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy; Diabetic Macular Edema
• 4) By Macular Degeneration: Dry Macular Degeneration; Wet Macular Degeneration
• 5) By Macular Hole: Full-Thickness Macular Hole; Lamellar Macular Hole; Tractional Macular Hole
• 6) By Other Types: Epiretinal Membrane; Retinal Vein Occlusion; Retinal Artery Occlusion; Retinitis Pigmentosa; Uveitis; Vitreous Hemorrhage; Macular Edema; Central Serous Retinopathy; Proliferative Vitreoretinopathy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vitreoretinal Disorder Market Characteristics

3. Vitreoretinal Disorder Market Trends And Strategies

4. Vitreoretinal Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vitreoretinal Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vitreoretinal Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vitreoretinal Disorder Market Growth Rate Analysis
• 5.4. Global Vitreoretinal Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vitreoretinal Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vitreoretinal Disorder Total Addressable Market (TAM)

6. Vitreoretinal Disorder Market Segmentation

• 6.1. Global Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retinal Tear
• Retinal Detachment
• Diabetic Retinopathy
• Macular Degeneration
• Macular Hole
• Other Types
• 6.2. Global Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Digital Fluorescein Angiography
• Optical Coherence Tomography
• Heidelberg Retinal Tomography
• Indocyanine Green Angiography
• Other Diagnosis
• 6.3. Global Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Medication
• Other Treatments
• 6.4. Global Vitreoretinal Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Vitreoretinal Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Tear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atrophic Retinal Tear
• Operculated Retinal Tear
• Horseshoe Retinal Tear
• Giant Retinal Tear
• 6.7. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Detachment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rhegmatogenous Retinal Detachment
• Tractional Retinal Detachment
• Exudative Retinal Detachment
• 6.8. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Diabetic Retinopathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema
• 6.9. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Macular Degeneration
• Wet Macular Degeneration
• 6.10. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Hole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Full-Thickness Macular Hole
• Lamellar Macular Hole
• Tractional Macular Hole
• 6.11. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epiretinal Membrane
• Retinal Vein Occlusion
• Retinal Artery Occlusion
• Retinitis Pigmentosa
• Uveitis
• Vitreous Hemorrhage
• Macular Edema
• Central Serous Retinopathy
• Proliferative Vitreoretinopathy

7. Vitreoretinal Disorder Market Regional And Country Analysis

• 7.1. Global Vitreoretinal Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vitreoretinal Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vitreoretinal Disorder Market

• 8.1. Asia-Pacific Vitreoretinal Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vitreoretinal Disorder Market

• 9.1. China Vitreoretinal Disorder Market Overview
• 9.2. China Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vitreoretinal Disorder Market

• 10.1. India Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vitreoretinal Disorder Market

• 11.1. Japan Vitreoretinal Disorder Market Overview
• 11.2. Japan Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vitreoretinal Disorder Market

• 12.1. Australia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vitreoretinal Disorder Market

• 13.1. Indonesia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vitreoretinal Disorder Market

• 14.1. South Korea Vitreoretinal Disorder Market Overview
• 14.2. South Korea Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vitreoretinal Disorder Market

• 15.1. Western Europe Vitreoretinal Disorder Market Overview
• 15.2. Western Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vitreoretinal Disorder Market

• 16.1. UK Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vitreoretinal Disorder Market

• 17.1. Germany Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vitreoretinal Disorder Market

• 18.1. France Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vitreoretinal Disorder Market

• 19.1. Italy Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vitreoretinal Disorder Market

• 20.1. Spain Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vitreoretinal Disorder Market

• 21.1. Eastern Europe Vitreoretinal Disorder Market Overview
• 21.2. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vitreoretinal Disorder Market

• 22.1. Russia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vitreoretinal Disorder Market

• 23.1. North America Vitreoretinal Disorder Market Overview
• 23.2. North America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vitreoretinal Disorder Market

• 24.1. USA Vitreoretinal Disorder Market Overview
• 24.2. USA Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vitreoretinal Disorder Market

• 25.1. Canada Vitreoretinal Disorder Market Overview
• 25.2. Canada Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vitreoretinal Disorder Market

• 26.1. South America Vitreoretinal Disorder Market Overview
• 26.2. South America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vitreoretinal Disorder Market

• 27.1. Brazil Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vitreoretinal Disorder Market

• 28.1. Middle East Vitreoretinal Disorder Market Overview
• 28.2. Middle East Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vitreoretinal Disorder Market

• 29.1. Africa Vitreoretinal Disorder Market Overview
• 29.2. Africa Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vitreoretinal Disorder Market Competitive Landscape And Company Profiles

• 30.1. Vitreoretinal Disorder Market Competitive Landscape
• 30.2. Vitreoretinal Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Vitreoretinal Disorder Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Baxter International
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Alcon Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Topcon Corporation
• 31.12. Ocular Therapeutix Inc.
• 31.13. Carl Zeiss Meditec AG
• 31.14. EyePoint Pharmaceuticals Inc.
• 31.15. Kodiak Sciences Inc.

32. Global Vitreoretinal Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vitreoretinal Disorder Market

34. Recent Developments In The Vitreoretinal Disorder Market

35. Vitreoretinal Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Vitreoretinal Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vitreoretinal Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vitreoretinal Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35026_Vitreoretinal_Disorder_GMR_2025